blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2820151

EP2820151 - CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  21.02.2020
Database last updated on 03.09.2024
FormerGrant of patent is intended
Status updated on  01.10.2019
FormerExamination is in progress
Status updated on  15.11.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2015/34]
Former [2015/02]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For all designated states
IRM LLC
131 Front Street P.O. Box HM 2899
Hamilton HM LX / BM
Inventor(s)01 / CONG, Feng
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
02 / HAO, Huaixiang
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
03 / HSIEH, Hsin-i
Genomics Institute of the Novartis
Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
04 / JIANG, Xiaomo
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
05 / LIU, Jun
Genomics Institute of the Novartis
Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
06 / NG, Nicholas
Genomics Institute of the Novartis
Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
 [2020/13]
Former [2015/02]01 / CONG, Feng
Novartis Institutes for Biomedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
02 / HAO, Huaixiang
Novartis Institutes for Biomedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
03 / HSIEH, Hsin-i
Genomics Institute of the Novartis
Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
04 / JIANG, Xiaomo
Novartis Institutes for Biomedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
05 / LIU, Jun
Genomics Institute of the Novartis
Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
06 / NG, Nicholas
Genomics Institute of the Novartis
Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
Representative(s)Kristl, Jernej, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
[2020/13]
Former [2015/02]Kristl, Jernej
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date13707527.122.02.2013
[2020/13]
WO2013US27441
Priority number, dateUS201261604290P28.02.2012         Original published format: US 201261604290 P
[2015/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013130364
Date:06.09.2013
Language:EN
[2013/36]
Type: A1 Application with search report 
No.:EP2820151
Date:07.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 06.09.2013 takes the place of the publication of the European patent application.
[2015/02]
Type: B1 Patent specification 
No.:EP2820151
Date:25.03.2020
Language:EN
[2020/13]
Search report(s)International search report - published on:EP06.09.2013
ClassificationIPC:C12Q1/68
[2015/02]
CPC:
C12Q1/6886 (EP,CN,RU,US); G01N33/57438 (RU,US); C12Q1/68 (KR);
A61K31/497 (EP,RU,US); A61P1/18 (EP); A61P35/00 (EP);
A61P43/00 (EP); G01N33/57492 (RU,US); C12Q2600/106 (EP,CN,RU,US);
C12Q2600/156 (RU,US); C12Q2600/158 (EP,CN,RU,US); G01N2800/52 (RU,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/02]
Extension statesBA29.09.2014
ME29.09.2014
TitleGerman:KREBSPATIENTENAUSWAHL ZUR VERABREICHUNG VON WNT-SIGNALÜBERTRAGUNGSHEMMERN UNTER VERWENDUNG EINER RNF43-STATUS-MUTATION[2015/02]
English:CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS[2015/02]
French:SÉLECTION DE PATIENTS ATTEINTS D'UN CANCER POUR ADMINISTRER DES INHIBITEURS DE SIGNALISATION DE LA VOIE WNT AU MOYEN DE L'ÉTAT DE MUTATION RNF43[2019/44]
Former [2015/02]SÉLECTION DE PATIENT ATTEINTS D'UN CANCER POUR ADMINISTRER DES INHIBITEURS DE SIGNALISATION DE LA VOIE WNT AU MOYEN DE L'ÉTAT DE MUTATION RNF43
Entry into regional phase29.09.2014National basic fee paid 
29.09.2014Designation fee(s) paid 
29.09.2014Examination fee paid 
Examination procedure29.09.2014Examination requested  [2015/02]
10.04.2015Amendment by applicant (claims and/or description)
22.02.2016Despatch of a communication from the examining division (Time limit: M04)
21.06.2016Reply to a communication from the examining division
04.11.2016Despatch of a communication from the examining division (Time limit: M04)
01.12.2016Reply to a communication from the examining division
01.03.2017Despatch of a communication from the examining division (Time limit: M04)
14.06.2017Reply to a communication from the examining division
11.07.2017Observations by third parties
06.10.2017Despatch of a communication from the examining division (Time limit: M06)
16.05.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
23.07.2018Reply to a communication from the examining division
08.10.2018Despatch of a communication from the examining division (Time limit: M06)
23.04.2019Reply to a communication from the examining division
14.05.2019Observations by third parties
02.10.2019Communication of intention to grant the patent
28.01.2020Fee for grant paid
28.01.2020Fee for publishing/printing paid
28.01.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20154250.3  / EP3693476
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.02.2016
Opposition(s)Opponent(s)01  15.12.2020  16.12.2021  WITHDRAWN
Boehringer Ingelheim RCV GmbH & Co KG / Boehringer Ingelheim International GmbH
Dr. Boehringer-Gasse 5-11 / Binger Strasse 173
AT-1121 Wien / DE-55216 Ingelheim am Rhein / AT
Opponent's representative
D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
 [N/P]
Former [2022/03]
Opponent(s)01  15.12.2020  16.12.2021  WITHDRAWN
Boehringer Ingelheim RCV GmbH & Co KG / Boehringer Ingelheim International GmbH
Dr. Boehringer-Gasse 5-11 / Binger Strasse 173
AT-1121 Wien / DE-55216 Ingelheim am Rhein / AT
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2021/03]
Opponent(s)01  15.12.2020   
Boehringer Ingelheim RCV GmbH & Co KG / Boehringer Ingelheim International GmbH
Dr. Boehringer-Gasse 5-11 / Binger Strasse 173
AT-1121 Wien / DE-55216 Ingelheim am Rhein / AT
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
28.01.2021Invitation to proprietor to file observations on the notice of opposition
07.06.2021Reply of patent proprietor to notice(s) of opposition
20.01.2022Despatch of communication that the opposition procedure will be closed
30.01.2022Legal effect of closure of opposition procedure [2022/24]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
23.04.2019Request for further processing filed
23.04.2019Full payment received (date of receipt of payment)
Request granted
08.05.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
23.07.2018Request for further processing filed
23.07.2018Full payment received (date of receipt of payment)
Request granted
02.08.2018Decision despatched
Fees paidRenewal fee
11.02.2015Renewal fee patent year 03
10.02.2016Renewal fee patent year 04
10.02.2017Renewal fee patent year 05
14.02.2018Renewal fee patent year 06
13.02.2019Renewal fee patent year 07
13.02.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.02.2013
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MK25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
IE22.02.2021
LU22.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
[2024/22]
Former [2023/30]HU22.02.2013
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
IE22.02.2021
LU22.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
Former [2023/27]HU22.02.2013
AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
IE22.02.2021
LU22.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
Former [2022/33]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
IE22.02.2021
LU22.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
Former [2022/07]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
IE22.02.2021
LU22.02.2021
CH28.02.2021
LI28.02.2021
Former [2021/47]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
LU22.02.2021
CH28.02.2021
LI28.02.2021
Former [2021/41]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/24]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/11]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/08]CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/50]CZ25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/49]CZ25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/48]FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/47]FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
Former [2020/46]FI25.03.2020
HR25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
Former [2020/45]FI25.03.2020
HR25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
Former [2020/39]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
Former [2020/38]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
NO25.06.2020
GR26.06.2020
Former [2020/37]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
NO25.06.2020
Former [2020/35]FI25.03.2020
NO25.06.2020
Cited inInternational search[Y]WO2004032838  (UNIV CALIFORNIA [US], et al) [Y] 1,2,9-15,26-30 * examples 2, 5; claim 24 *;
 [IY]WO2006017318  (UNIV CALIFORNIA [US], et al) [I] 1,4,5,7,26-30 * example 12; claims 35, 40, 41, 43 * [Y] 1,2,9-15,26-30;
 [Y]WO2011004379  (TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD [IL], et al) [Y] 1,2,9-15,26-30 * example 5; claim 5 *;
 [XI]EP2275544  (ONCOTHERAPY SCIENCE INC [JP]) [X] 16,18,20,24,25 * paragraphs [0194] , [ 245] , [ 246]; sequence 6 * [I] 17,22;
 [I]  - J. LIU ET AL, "PD08-11: Targeting Porcupine, a Critical Node for Wnt Signalling in Cancer.", CANCER RESEARCH, (20111215), vol. 71, no. 24 Supplement, doi:10.1158/0008-5472.SABCS11-PD08-11, ISSN 0008-5472, pages PD08 - 11, XP055061279 [I] 26-30 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.SABCS11-PD08-11
 [XP]  - HUAI-XIANG HAO ET AL, "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner", NATURE, (20120429), vol. 485, no. 7397, doi:10.1038/nature11019, ISSN 0028-0836, pages 195 - 200, XP055061275 [XP] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature11019
 [XP]  - BON-KYOUNG KOO ET AL, "Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors", NATURE, (20120815), vol. 488, no. 7413, doi:10.1038/nature11308, ISSN 0028-0836, pages 665 - 669, XP055061276 [XP] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature11308
by applicantWO03024392
 US7425612
 US7718364
 WO2010101849
 EP1487877
 US8093011
    - NUSSE R, CELL RESEARCH, (2005), vol. 15, no. 1, pages 28 - 32
    - MCDONALD BT ET AL., DEVELOPMENTAL CELL, (2009), vol. 17, no. 1, pages 9 - 26
    - HAO HX ET AL., NATURE, (2012), vol. 485, no. 7397, pages 195 - 200
    - SUGIURA T ET AL., EXP. CELL RES., (2008), vol. 314, no. 7, pages 1519 - 28
    - MATTHAEI H ET AL., ANN. SURG. ONCOL., (2011), vol. 18, no. 12, pages 3493 - 9
    - LUEBKE AM ET AL., PANCREATOLOGY, (2012), vol. 12, no. 1, pages 16 - 22
    - HEZEL AF, GENES DEV., (2006), vol. 20, no. 10
    - WELLS JM, BMC DEV. BIOL., (2007), vol. 7, page 4
    - HEISER PW ET AL., DEVELOPMENT, (2006), vol. 133, no. 10, pages 2023 - 32
    - MORRIS JP ET AL., NAT. REV. CANCER, (2010), vol. 10, no. 10, pages 683 - 95
    - PASCA DI MAGLIANO M ET AL., PLOS ONE, (2007), vol. 2, no. 11, page E1155
    - WANG L ET AL., CANCER SCI., (2009), vol. 101, no. 3, pages 700 - 6
    - FURUKAWA T ET AL., SCI. REP., (2011), vol. 1, page 161
    - WU J ET AL., PROC. NATL. ACAD. SCI. USA, (2011), vol. 108, no. 52, pages 21188 - 93
    - WU J ET AL., PROC. NATL. ACAD. SCI., (2011), vol. 108, page 2188
    - KOO BK ET AL., NATURE, (2012), vol. 488, no. 7413, pages 665 - 9
    - LOGAN CY; NUSSE R, ANNU. REV. CELL. DEV. BIOL., (2004), vol. 20, pages 781 - 810
    - CLEVERS H, CELL, (2006), vol. 127, no. 3, pages 469 - 80
    - MACDONALD BT ET AL., DEV. CELL, (2009), vol. 17, no. 1, pages 9 - 26
    - ETTENBERG S ET AL., PROC. NATL. ACAD. SCI. USA, (2010), vol. 107, no. 35, pages 15473 - 8
    - GURNEY A ET AL., PROC. NATL. ACAD. SCI. USA, (2012), vol. 109, no. 29, pages 11717 - 22
    - CHEN B ET AL., NAT. CHEM. BIOL., (2009), vol. 5, no. 2, pages 100 - 7
    - LASKO ET AL., ANNU. REV. GENET., (1991), vol. 25, pages 281 - 314
    - VOGELSTEIN ET AL., NEW ENGL. J. MED., (1988), vol. 319, no. 9, pages 525 - 532
    - FEARON ET AL., CELL, (1990), vol. 61, pages 759 - 767
    - FRIEND ET AL., NATURE, (1986), vol. 323, pages 643 - 646
    - CALL ET AL., CELL, (1990), vol. 60, pages 509 - 520
    - KINZLER ET AL., SCIENCE, (1991), vol. 253, pages 661 - 665
    - BAKER ET AL., SCIENCE, (1989), vol. 244, pages 217 - 221
    - THERASSE P. ET AL., J. NATL. CANCER INST., (2000), vol. 92, no. 3, pages 205 - 216
    - THERASSE P ET AL., J. NATL. CANCER INST., (2000), vol. 92, no. 3, pages 205 - 216
    - ROGAN P ET AL., GENOME RES., (2001), vol. 11, no. 6, pages 1086 - 1094
    - MEINKOTH ET AL., ANAL. BIOCHEM., (1984), vol. 138, pages 267 - 284
    - SAMBROOK ET AL., Molecular Cloning: A Laboratory Manual, COLD SPRING HARBOR LABS PRESS, (1989), pages 9.31 - 9.62
    - CHEN B ET AL., NATURE CHEM. BIOL, (2009), vol. 5, pages 100 - 107
    - HUANG SM ET AL., NATURE, (2009), vol. 461, no. 7264, pages 614 - 20
    - DEALMEIDA VI ET AL., CANCER RES., (2007), vol. 67, no. 11, pages 5371 - 9
    - HAO H-X ET AL., NATURE, (2012), vol. 485, no. 7397, pages 195 - 200
    - KOO BK, NATURE, (2012), vol. 488, no. 7413, pages 665 - 9
    - SCHOLER-DAHIREL A ET AL., PROC. NATL. ACAD. SCI. USA, (2011), vol. 108, no. 41, pages 17135 - 40
OppositionWO2013011479
 WO2013054307
 EP2820151
 WO2017093478
    - SATO et al., "MAINTENANCE OF PLURIPOTENCY IN HUMAN AND MOUSE EMBRYONIC STEM CELLS THROUGH ACTIVATION OF WNT SIGNALING BY A PHARMACOLOGICAL GSK-3-SPECIFIC INHIBITOR", Nature Medicine, (20040000), vol. 10, no. 1, pages 55 - 63, XP002380572
    - RING et al., "Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo", Diabetes, (20030000), vol. 52, pages 588 - 595, XP002305100

DOI:   http://dx.doi.org/10.2337/diabetes.52.3.588
    - Huai-Xiang Hao; Yang Xie; Yue Zhang; Olga Charlat; Emma Oster; Monika Avello; Hong Lei; Craig Mickanin; Dong Liu; Heinz Ruffner; Xiaohong Mao; Qicheng Ma; Raffaella Zamponi; Tewis Bouwmeester; Peter M Finan; Marc W Kirschner; Jeffery A Porter; Fabrizio C Serluca; Feng Cong, "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner", Nature, (20120000), vol. 485, no. 7397, pages 195 - 200, XP002706010

DOI:   http://dx.doi.org/10.1038/NATURE11019
    - Bon-Kyoung Koo; Maureen Spit; Ingrid Jordens; Teck Y Low; Daniel E Stange; Marc van de Wetering; Johan H van Es; Shabaz Mohammed; Albert J R Heck; Madelon M Maurice; Hans Clevers, "Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors", Nature, (20120000), vol. 488, pages 665 - 669, XP002696011

DOI:   http://dx.doi.org/10.1038/nature11308
    - Dong Guo, Siu Yuen, Wai Tsui, Annie Chan, Tsun Chan and Suet Leung, "Expression of wnt signaling target genes in colorectal cancer progression", AACR annual meeting, (20070000), pages 1 - 3, XP055783273
    - IVANOV et al., "Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells", Oncogene, (20070000), vol. 26, pages 2873 - 2884, XP055783277
    - Wu J; Jiao Y; Dal Molin M; Maitra A; De Wilde R F; Wood L D; Eshleman J R; Goggins M G; Wolfgang C L; Canto M I; Schulick R D; Edil B H; Choti M A; Adsay V; Klimstra D S; Offerhaus G J A; Klein A P; Kopelovich L; Carter H; Karchin R; Allen P J; Schmidt C M; Naito Y; Diaz L A; Kinzler K W; Papadopoulos N; Hruban R H; Vogelstein B, "Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways", PNAS, (20110000), vol. 108, no. 52, pages 21188 - 21193, XP055069412

DOI:   http://dx.doi.org/10.1073/pnas.1118046108
    - Baozhi Chen; Michael E Dodge; Wei Tang; Jianming Lu; Zhiqiang Ma; Chih-Wei Fan; Shuguang Wei; Wayne Hao; Jessica Kilgore; Noelle S Williams; Michael G Roth; James F Amatruda; Chuo Chen; Lawrence Lum, "Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer", Nat Chem Biol, (20090000), vol. 5, no. 2, pages 100 - 107, XP055295218

DOI:   http://dx.doi.org/10.1038/nchembio.137
    - Liu J; Pan S; Sun F; Kasibhatla S; Schuller A; Li A; Li C; Cui X; Wang T; Villarroel M; Mclaughlin M; Sellers W; Boral A; Harris J, "PD08-11: Targeting Porcupine, a Critical Node for Wnt Signalling in Cancer", Cancer Research, (20110000), vol. 71, no. 24, page PD08-11, XP055061279

DOI:   http://dx.doi.org/10.1158/0008-5472.SABCS11-PD08-11
    - NUSSE R., "Wnt signaling in disease and in development", Cell Research, (20050000), vol. 15, no. 1, pages 28 - 32, XP055783283
    - Aguilera O; Fraga M F; Ballestar E; Paz M F; Herranz M; Espada J; García J M; Muñoz A; Esteller M; González-Sancho J M, "Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer", Oncogene, (20060000), vol. 25, no. 29, pages 4116 - 4121, XP002679453

DOI:   http://dx.doi.org/10.1038/SJ.ONC.1209439
    - Akiko Mukai, Miki Yamamoto-Hino, Wakae Awano, Wakako Watanabe, Masayuki Komada, Satoshi Goto, "Balanced ubiquitylation and deubiquitylation of frizzled regulate cellular responsiveness to Wg/Wnt", The EMBO Journal, (20100000), vol. 29, no. 13, pages 2114 - 2125, XP055783291
    - CAIRO et al., "Hepatic Stem-like Phenotype and Interplay of Wnt/beta-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer", Cancer Cell, (20080000), vol. 14, pages 471 - 484, XP002508978

DOI:   http://dx.doi.org/10.1016/J.CCR.2008.11.002
    - Daniel Bottomly, Sydney L. Kyler, Shannon K. McWeeney, and Gregory S. Yochum, "Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq", Nucleic Acids Research, (20100000), vol. 38, no. 17, pages 5735 - 5745, XP055783300
    - Anonymous, "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", ClinicalTrials.gov, (20110500), pages 1 - 9, XP002780915
    - Toru Furukawa; Yuko Kuboki; Etsuko Tanji; Shoko Yoshida; Takashi Hatori; Masakazu Yamamoto; Noriyuki Shibata; Kyoko Shimizu; Naoyuki Kamatani; and Keiko Shiratori, "Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas", Scientific Reports, (20110000), vol. 1, no. 161, pages 1 - 7, XP002733929

DOI:   http://dx.doi.org/10.1038/srep00161
    - Anonymous, "Small molecules in Wnt signalling", the Wnt homepage, (20180123), page 1, URL: https://web.stanford.edu/group/nusselab/cgi/bin/wnt/smallmolecules, XP055783318
    - Jiang X; H-X Hao; Growney J D; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh M H; Bagdasarian L; Meyer R; Smith T R; Avello M; Charlat O; Xie Y; Porter J A; Pan S; Liu J; Mclaughlin M E; Cong F, "Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma", PNAS, (20130000), vol. 110, no. 31, pages 12649 - 12654, XP055200712

DOI:   http://dx.doi.org/10.1073/pnas.1307218110
    - Jianghua Tu , Soohyun Park , Wangsheng Yu , Sheng Zhang , Ling Wu , Kendra Carmon , Qingyun J Liu, "The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis", Sci Rep, (20190000), vol. 9, no. 18557, pages 1 - 12, XP055783323
    - Li Shan; Lavrijsen Marla; Bakker Aron; Magierowski Marcin; Magierowska Katarzyna; Liu Pengyu; Wang Wenhui; Peppelenbosch Maikel P; Smits Ron, "Commonly observedmutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers", Oncogene, (20200000), vol. 39, pages 3458 - 3472, XP037098180

DOI:   http://dx.doi.org/10.1038/s41388-020-1232-5
    - Kyoung-Sub Song , Kaipeng Jing, Jong-Seok Kim, Eun-Jin Yun, Soyeon Shin, Kang-Sik Seo, Ji-Hoon Park, Jun-Young Heo, Jing X Kang, Kwang-Sun Suh, Tong Wu, Jong-Il Park, Gi-Ryang Kweon, Wan-Hee Yoon, Byung-Doo Hwang, Kyu Lim, "Omeda-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-Catenin Signaling", Pancreatology, (20110000), vol. 11, pages 574 - 584, XP055783337
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.